Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease

Seong Mi Moon, Hye Yun Park, Su Young Kim, Byung Woo Jhun, Hyun Lee, Kyeongman Jeon, Dae Hun Kim, Hee Jae Huh, Chang Seok Ki, Nam Yong Lee, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Seung Heon Lee, Chang Ki Kim, Sung Jae Shin, Charles L. Daley, Won Jung Koh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due to Mycobacterium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide-resistant MAC-LD and the molecular characteristics of the macrolide-resistant isolates. A retrospective review of the medical records of 34 patients with macrolide-resistant MAC-LD who were diagnosed between January 2002 and December 2014 was performed, along with genetic analysis of 28 clinical isolates. Nineteen (56%) patients had the fibrocavitary form of MAC-LD, and 15 (44%) had the nodular bronchiectatic form. M. intracellulare was the etiologic organism in 21 (62%) patients. Approximately two-Thirds (22/34 [65%]) of the patients had been treated with currently recommended multidrug regimens that included macrolide, ethambutol, and rifamycin prior to the emergence of macrolide resistance, and none had been treated with macrolide monotherapy. The median duration of treatment after the detection of macrolide resistance was 23.0 months (interquartile range, 16.8 to 45.3 months). Treatment outcomes were poor after the development of macrolide resistance, with favorable treatment outcomes achieved in only five (15%) patients, including two patients who underwent surgical resection. One-, 3-, and 5-year mortality rates were 9, 24, and 47%, respectively. Molecular analysis of 28 clinical isolates revealed that 96% (27/28) had point mutations at position 2058 or 2059 of the 23S rRNA gene. Our analyses indicate that more effective therapy is needed to treat macrolide-resistant MAC-LD and prevent its development.

Original languageEnglish
Pages (from-to)6758-6765
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1
Externally publishedYes

Fingerprint

Mycobacterium avium Complex
Macrolides
Lung Diseases
Mutation
Ethambutol
rRNA Genes
Point Mutation
Medical Records
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease. / Moon, Seong Mi; Park, Hye Yun; Kim, Su Young; Jhun, Byung Woo; Lee, Hyun; Jeon, Kyeongman; Kim, Dae Hun; Huh, Hee Jae; Ki, Chang Seok; Lee, Nam Yong; Kim, Hong Kwan; Choi, Yong Soo; Kim, Jhingook; Lee, Seung Heon; Kim, Chang Ki; Shin, Sung Jae; Daley, Charles L.; Koh, Won Jung.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 11, 01.11.2016, p. 6758-6765.

Research output: Contribution to journalArticle

Moon, SM, Park, HY, Kim, SY, Jhun, BW, Lee, H, Jeon, K, Kim, DH, Huh, HJ, Ki, CS, Lee, NY, Kim, HK, Choi, YS, Kim, J, Lee, SH, Kim, CK, Shin, SJ, Daley, CL & Koh, WJ 2016, 'Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease', Antimicrobial Agents and Chemotherapy, vol. 60, no. 11, pp. 6758-6765. https://doi.org/10.1128/AAC.01240-16
Moon, Seong Mi ; Park, Hye Yun ; Kim, Su Young ; Jhun, Byung Woo ; Lee, Hyun ; Jeon, Kyeongman ; Kim, Dae Hun ; Huh, Hee Jae ; Ki, Chang Seok ; Lee, Nam Yong ; Kim, Hong Kwan ; Choi, Yong Soo ; Kim, Jhingook ; Lee, Seung Heon ; Kim, Chang Ki ; Shin, Sung Jae ; Daley, Charles L. ; Koh, Won Jung. / Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 11. pp. 6758-6765.
@article{4f0e8ef3e29e4fa282277c5ae3846750,
title = "Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease",
abstract = "Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due to Mycobacterium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide-resistant MAC-LD and the molecular characteristics of the macrolide-resistant isolates. A retrospective review of the medical records of 34 patients with macrolide-resistant MAC-LD who were diagnosed between January 2002 and December 2014 was performed, along with genetic analysis of 28 clinical isolates. Nineteen (56{\%}) patients had the fibrocavitary form of MAC-LD, and 15 (44{\%}) had the nodular bronchiectatic form. M. intracellulare was the etiologic organism in 21 (62{\%}) patients. Approximately two-Thirds (22/34 [65{\%}]) of the patients had been treated with currently recommended multidrug regimens that included macrolide, ethambutol, and rifamycin prior to the emergence of macrolide resistance, and none had been treated with macrolide monotherapy. The median duration of treatment after the detection of macrolide resistance was 23.0 months (interquartile range, 16.8 to 45.3 months). Treatment outcomes were poor after the development of macrolide resistance, with favorable treatment outcomes achieved in only five (15{\%}) patients, including two patients who underwent surgical resection. One-, 3-, and 5-year mortality rates were 9, 24, and 47{\%}, respectively. Molecular analysis of 28 clinical isolates revealed that 96{\%} (27/28) had point mutations at position 2058 or 2059 of the 23S rRNA gene. Our analyses indicate that more effective therapy is needed to treat macrolide-resistant MAC-LD and prevent its development.",
author = "Moon, {Seong Mi} and Park, {Hye Yun} and Kim, {Su Young} and Jhun, {Byung Woo} and Hyun Lee and Kyeongman Jeon and Kim, {Dae Hun} and Huh, {Hee Jae} and Ki, {Chang Seok} and Lee, {Nam Yong} and Kim, {Hong Kwan} and Choi, {Yong Soo} and Jhingook Kim and Lee, {Seung Heon} and Kim, {Chang Ki} and Shin, {Sung Jae} and Daley, {Charles L.} and Koh, {Won Jung}",
year = "2016",
month = "11",
day = "1",
doi = "10.1128/AAC.01240-16",
language = "English",
volume = "60",
pages = "6758--6765",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease

AU - Moon, Seong Mi

AU - Park, Hye Yun

AU - Kim, Su Young

AU - Jhun, Byung Woo

AU - Lee, Hyun

AU - Jeon, Kyeongman

AU - Kim, Dae Hun

AU - Huh, Hee Jae

AU - Ki, Chang Seok

AU - Lee, Nam Yong

AU - Kim, Hong Kwan

AU - Choi, Yong Soo

AU - Kim, Jhingook

AU - Lee, Seung Heon

AU - Kim, Chang Ki

AU - Shin, Sung Jae

AU - Daley, Charles L.

AU - Koh, Won Jung

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due to Mycobacterium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide-resistant MAC-LD and the molecular characteristics of the macrolide-resistant isolates. A retrospective review of the medical records of 34 patients with macrolide-resistant MAC-LD who were diagnosed between January 2002 and December 2014 was performed, along with genetic analysis of 28 clinical isolates. Nineteen (56%) patients had the fibrocavitary form of MAC-LD, and 15 (44%) had the nodular bronchiectatic form. M. intracellulare was the etiologic organism in 21 (62%) patients. Approximately two-Thirds (22/34 [65%]) of the patients had been treated with currently recommended multidrug regimens that included macrolide, ethambutol, and rifamycin prior to the emergence of macrolide resistance, and none had been treated with macrolide monotherapy. The median duration of treatment after the detection of macrolide resistance was 23.0 months (interquartile range, 16.8 to 45.3 months). Treatment outcomes were poor after the development of macrolide resistance, with favorable treatment outcomes achieved in only five (15%) patients, including two patients who underwent surgical resection. One-, 3-, and 5-year mortality rates were 9, 24, and 47%, respectively. Molecular analysis of 28 clinical isolates revealed that 96% (27/28) had point mutations at position 2058 or 2059 of the 23S rRNA gene. Our analyses indicate that more effective therapy is needed to treat macrolide-resistant MAC-LD and prevent its development.

AB - Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due to Mycobacterium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide-resistant MAC-LD and the molecular characteristics of the macrolide-resistant isolates. A retrospective review of the medical records of 34 patients with macrolide-resistant MAC-LD who were diagnosed between January 2002 and December 2014 was performed, along with genetic analysis of 28 clinical isolates. Nineteen (56%) patients had the fibrocavitary form of MAC-LD, and 15 (44%) had the nodular bronchiectatic form. M. intracellulare was the etiologic organism in 21 (62%) patients. Approximately two-Thirds (22/34 [65%]) of the patients had been treated with currently recommended multidrug regimens that included macrolide, ethambutol, and rifamycin prior to the emergence of macrolide resistance, and none had been treated with macrolide monotherapy. The median duration of treatment after the detection of macrolide resistance was 23.0 months (interquartile range, 16.8 to 45.3 months). Treatment outcomes were poor after the development of macrolide resistance, with favorable treatment outcomes achieved in only five (15%) patients, including two patients who underwent surgical resection. One-, 3-, and 5-year mortality rates were 9, 24, and 47%, respectively. Molecular analysis of 28 clinical isolates revealed that 96% (27/28) had point mutations at position 2058 or 2059 of the 23S rRNA gene. Our analyses indicate that more effective therapy is needed to treat macrolide-resistant MAC-LD and prevent its development.

UR - http://www.scopus.com/inward/record.url?scp=84994885760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994885760&partnerID=8YFLogxK

U2 - 10.1128/AAC.01240-16

DO - 10.1128/AAC.01240-16

M3 - Article

C2 - 27572413

AN - SCOPUS:84994885760

VL - 60

SP - 6758

EP - 6765

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -